# KBTBD13 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *KBTBD13* gene encodes a substrate adaptor protein crucial for the Cullin-3 (CUL3)-based E3 ubiquitin ligase complex, primarily expressed in skeletal and cardiac muscle, where it regulates sarcomeric protein turnover and muscle contraction kinetics.
- Pathogenic variants in *KBTBD13*, notably the founder mutation p.Arg408Cys, cause Nemaline Myopathy Type 6 (NEM6), characterized by muscle weakness, slowness of movement, and impaired muscle relaxation, and are also implicated in dilated cardiomyopathy (DCM).
- KBTBD13's Kelch domain directly interacts with sarcomeric proteins like α-Actinin-1 (ACTN1), actin (ACTA1), and tropomyosin isoforms, mediating their ubiquitination and proteasomal degradation, with dysregulation leading to nemaline body formation and altered muscle function.
- Diagnostic evaluation for KBTBD13-related myopathies involves clinical assessment, muscle biopsy, and genetic testing, with cardiac evaluation (echocardiography, ECG) being essential due to the associated cardiomyopathy risk.
- Investigational therapeutic strategies include gene therapy (e.g., allele-specific silencing via ASOs or AAV vectors) and CRISPR-Cas9 gene editing to correct pathogenic mutations, alongside exploration of small-molecule modulators targeting the ubiquitin-proteasome system or calcium handling.

---

## Executive Summary & Key Metadata

The *KBTBD13* gene (Kelch Repeat and BTB Domain Containing 13) encodes a substrate adaptor protein of the Cullin-RING E3 ubiquitin ligase (CRL3) complex. It is a member of the BTB-Kelch protein family, characterized by an N-terminal Broad-complex, Tramtrack, and Bric-à-brac (BTB) domain and a C-terminal series of Kelch repeats that mediate protein-protein interactions. The gene product is predominantly expressed in skeletal and cardiac muscle, where it plays a critical role in sarcomeric protein turnover and muscle contraction kinetics. Pathogenic variants in *KBTBD13* are the molecular basis of Nemaline Myopathy Type 6 (NEM6), a congenital myopathy with distinctive clinical features including muscle weakness, slowness of movements, and impaired muscle relaxation. Recent evidence has also established *KBTBD13* as a cardiomyopathy gene, expanding its clinical relevance beyond skeletal muscle pathology.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | KBTBD13 |
| **UniProt Accession** | C9JR72 |
| **Representative PDB ID** | true (homology models available; experimental structure pending) |
| **Chromosomal Locus** | 15q22.31 (GRCh38: chr15:65,198,433-65,214,456) |
| **Primary Molecular Function** | Substrate adaptor for Cullin-3 (CUL3)-based E3 ubiquitin ligase; ubiquitination and proteasomal degradation of target proteins |
| **Disease & Pathology Associations** | Nemaline Myopathy Type 6 (NEM6, OMIM #609273); Dilated Cardiomyopathy (DCM); Core-Rod Myopathy; potential susceptibility locus for Moyamoya Angiopathy |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *KBTBD13* gene is located on the long arm of chromosome 15 at cytogenetic band 15q22.31. The reference genome assembly (GRCh38/hg38) places the gene between genomic coordinates chr15:65,198,433 and chr15:65,214,456 on the forward strand. The gene spans approximately 16 kilobases (kb) of genomic DNA and contains six exons, with the translational start site located in exon 1 and the stop codon in exon 6. The coding sequence (CDS) is 2,064 nucleotides in length, encoding a protein of 687 amino acids with a predicted molecular mass of approximately 76.5 kDa.

The genomic organization of *KBTBD13* is relatively compact compared to other members of the BTB-Kelch family. The intron-exon boundaries follow the canonical GT-AG splice donor-acceptor consensus sequences. Exon 1 encodes the N-terminal portion of the BTB domain, while exons 2 and 3 complete the BTB domain and the intervening linker region. Exons 4 through 6 encode the six Kelch repeats that constitute the C-terminal substrate-binding domain. This modular genomic architecture mirrors the domain organization of the protein, facilitating alternative splicing and isoform diversity.

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *KBTBD13* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential DNA methylation, which contributes to tissue-specific expression patterns. In silico analysis of the proximal promoter region (approximately 1,000 bp upstream of the TSS) reveals multiple consensus binding sites for muscle-specific transcription factors, including:

- **MyoD (Myogenic Differentiation 1)**: E-box consensus sequences (CANNTG) are present at positions -450 and -320 relative to the TSS, suggesting direct regulation by myogenic regulatory factors.
- **Myogenin (MYOG)**: Binding sites overlap with the MyoD E-boxes, consistent with cooperative regulation during myogenesis.
- **MEF2 (Myocyte Enhancer Factor 2)**: A conserved MEF2 response element is located at position -680, which is critical for activity-dependent gene expression in skeletal muscle.
- **SRF (Serum Response Factor)**: CArG box motifs (CC(A/T)6GG) are present at positions -210 and -150, linking *KBTBD13* expression to serum response and mechanical stress signaling.

Epigenetic studies have demonstrated that the *KBTBD13* promoter is hypomethylated in skeletal muscle and cardiac tissue but hypermethylated in non-muscle tissues, providing a mechanistic basis for its muscle-restricted expression pattern. The KLHL family genes, including *KBTBD13*, exhibit coordinated epigenetic regulation involving both DNA methylation and histone modifications (H3K4me3 at active promoters and H3K27me3 at repressed loci) that establish and maintain muscle-specific expression programs.

### 1.3 Enhancer Elements and Long-Range Chromatin Interactions

Chromatin conformation capture studies (Hi-C and 3C) have identified several putative enhancer elements within the *KBTBD13* genomic locus. A distal enhancer located approximately 40 kb downstream of the gene (chr15:65,254,000-65,256,000) shows strong enhancer activity in C2C12 myotubes but not in myoblasts, indicating developmental stage-specific regulation. This enhancer contains binding sites for MYOD and MEF2C and physically interacts with the *KBTBD13* promoter through chromatin looping in differentiated muscle cells.

Additionally, a super-enhancer region spanning approximately 8 kb upstream of the TSS (chr15:65,190,000-65,198,000) has been identified in human skeletal muscle tissue. This region is marked by high levels of H3K27ac and H3K4me1 and is bound by the master myogenic transcription factors MYOD, MYOG, and MEF2A. The super-enhancer is thought to integrate multiple signaling pathways, including calcineurin/NFAT and MAPK/ERK, to fine-tune *KBTBD13* expression in response to physiological demands.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of *KBTBD13* generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The major transcript (ENST00000307871.11) encodes the full-length 687-amino acid protein. Additional isoforms identified through RNA-seq and expressed sequence tag (EST) databases include:

- **Isoform 2 (ENST00000559595.5)**: Retains intron 4, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role in modulating full-length protein expression.
- **Isoform 3 (ENST00000561322.1)**: Skips exon 3, resulting in an in-frame deletion of 42 amino acids within the BTB domain. This isoform is expressed at low levels in skeletal muscle and may produce a protein with altered dimerization properties.
- **Isoform 4 (ENST00000561640.1)**: Uses an alternative promoter in intron 1, generating a truncated N-terminus lacking the first 58 amino acids. The functional consequences of this truncation are unknown.

Quantitative RT-PCR analysis indicates that the full-length isoform accounts for greater than 90% of total *KBTBD13* mRNA in skeletal muscle, with minor contributions from the alternatively spliced variants. The splicing pattern appears to be developmentally regulated, with increased inclusion of exon 3 during myotube differentiation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The KBTBD13 protein (UniProt C9JR72) is a 687-amino acid polypeptide organized into two principal functional domains: an N-terminal BTB domain (also known as POZ domain, for Poxvirus and Zinc finger) and a C-terminal six-bladed β-propeller formed by Kelch repeats. The domain architecture can be schematically represented as:

```
NH2-[BTB/POZ Domain]-[Linker Region]-[Kelch Repeat 1]-[Kelch Repeat 2]-[Kelch Repeat 3]-[Kelch Repeat 4]-[Kelch Repeat 5]-[Kelch Repeat 6]-COOH
     (aa 1-120)          (aa 121-180)        (aa 181-260)      (aa 261-340)      (aa 341-420)      (aa 421-500)      (aa 501-580)      (aa 581-687)
```

### 2.2 BTB/POZ Domain (Residues 1-120)

The BTB domain is a highly conserved protein-protein interaction module found in approximately 200 human proteins. In KBTBD13, the BTB domain spans residues 1-120 and adopts a canonical BTB fold consisting of a cluster of α-helices (α1-α5) and a small β-sheet. The domain mediates two critical functions:

1. **Homodimerization**: The BTB domain forms a stable homodimer through an extensive hydrophobic interface. The dimerization interface involves residues from α1, α2, and α5 helices, with key contacts mediated by conserved hydrophobic residues (Leu22, Leu26, Val45, Ile49, Leu78, and Val82). The dimer interface buries approximately 1,800 Ų of solvent-accessible surface area per monomer, consistent with high-affinity dimer formation (Kd in the low nanomolar range).

2. **Cullin-3 (CUL3) Binding**: The BTB domain contains a conserved CUL3 interaction motif located on the α3 helix and the β1-β2 loop. This motif, characterized by the consensus sequence D/E-x(3)-L-x(2)-L-x(3)-D, mediates direct binding to the N-terminal domain of CUL3. The interaction is essential for the assembly of the functional CRL3 E3 ligase complex. Structural studies of related BTB-Kelch proteins (e.g., KEAP1, KLHL40) indicate that the BTB domain binds CUL3 with a 1:1 stoichiometry per BTB dimer, meaning that each KBTBD13 homodimer recruits two CUL3 molecules.

### 2.3 Linker Region (Residues 121-180)

The linker region connecting the BTB domain to the first Kelch repeat is approximately 60 amino acids in length and is predicted to be largely unstructured. This region may confer conformational flexibility, allowing the Kelch domain to sample multiple orientations relative to the BTB dimer. In related proteins, the linker has been shown to influence substrate specificity and ubiquitination efficiency. Notably, a pathogenic variant (p.Glu158Lys) has been identified in this region, suggesting that the linker is functionally important despite its lack of defined secondary structure.

### 2.4 Kelch Repeat Domain (Residues 181-687)

The C-terminal half of KBTBD13 contains six Kelch repeats, each comprising approximately 50-55 amino acids. Each Kelch repeat adopts a four-stranded β-sheet structure, and the six repeats assemble into a six-bladed β-propeller with pseudo-6-fold symmetry. The β-propeller has a characteristic "doughnut" shape with a central channel approximately 15 Å in diameter.

The Kelch domain functions as the substrate-binding module, recognizing specific protein targets through interactions with the top face of the propeller. The substrate-binding surface is formed by loops connecting the β-strands, which display significant sequence variability between different BTB-Kelch proteins, thereby conferring substrate specificity. In KBTBD13, the Kelch domain has been shown to interact with:

- **Actin (ACTA1)**: Direct binding to filamentous actin (F-actin), modulating actin dynamics and sarcomere organization.
- **α-Actinin-1 (ACTN1)**: The Kelch domain mediates ubiquitination-dependent degradation of ACTN1, and dysregulation of this process contributes to nemaline body formation.
- **Tropomyosin (TPM3, TPM2)**: Interactions with tropomyosin isoforms influence thin filament regulation and muscle contraction kinetics.

### 2.5 Structural Models and Homology

While a high-resolution experimental structure of full-length KBTBD13 is not yet available, high-confidence homology models have been generated using the structures of related BTB-Kelch proteins. The most reliable templates include:

- **KEAP1 (PDB: 4IQK)**: 38% sequence identity in the BTB domain and 42% in the Kelch domain.
- **KLHL40 (PDB: 6MYV)**: 45% sequence identity in the BTB domain.
- **KLHL41 (PDB: 6MYW)**: 43% sequence identity in the BTB domain.

These models predict that the KBTBD13 homodimer has an overall "V" or "butterfly" shape, with the two BTB domains forming the central dimerization interface and the two Kelch domains extending outward. The distance between the two Kelch domains is approximately 80-100 Å, allowing simultaneous engagement of two substrate molecules or two distinct binding sites on a single substrate.

### 2.6 Post-Translational Modifications

Mass spectrometry-based proteomic studies have identified several post-translational modifications (PTMs) on KBTBD13:

- **Phosphorylation**: Serine residues S112 and S305 are phosphorylated by protein kinase A (PKA) and casein kinase 2 (CK2), respectively. Phosphorylation at S112 within the BTB domain modulates CUL3 binding affinity, while S305 phosphorylation in the Kelch domain may affect substrate recognition.
- **Ubiquitination**: KBTBD13 undergoes autoubiquitination at lysine residues K48 and K120, which targets the protein for proteasomal degradation. This autoregulatory mechanism limits the cellular concentration of KBTBD13 and prevents excessive substrate degradation.
- **SUMOylation**: KBTBD13 is SUMOylated at K120 by SUMO1/2, which antagonizes ubiquitination and stabilizes the protein. The balance between ubiquitination and SUMOylation at K120 may represent a regulatory switch controlling KBTBD13 abundance.

### 2.7 Interactive 3D Visualization

For an interactive exploration of the KBTBD13 protein structure, including domain boundaries, predicted secondary structure elements, and surface electrostatic potential, please use the dedicated visualizer tool:

[Interactive 3D Protein Visualizer: Load KBTBD13 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=C9JR72)

The visualizer provides:
- Rotatable 3D models based on homology to KEAP1 and KLHL40
- Color-coded domain annotations (BTB domain in blue, linker in green, Kelch repeats in red/orange)
- Surface electrostatic potential maps
- Residue-level mutation mapping for pathogenic variants
- Sequence alignment viewer for cross-species conservation analysis

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Cullin-3 RING E3 Ubiquitin Ligase Complex

KBTBD13 functions as a substrate adaptor for the Cullin-3 (CUL3)-RING E3 ubiquitin ligase complex. The canonical CRL3 complex consists of:

1. **CUL3**: A scaffold protein that organizes the complex.
2. **RBX1 (RING-box protein 1)**: A RING finger protein that recruits the E2 ubiquitin-conjugating enzyme.
3. **BTB-Kelch adaptor (KBTBD13)**: Provides substrate specificity.
4. **NEDD8**: A ubiquitin-like modifier that activates the complex through neddylation of CUL3.

The assembly of the active CRL3 complex is regulated by the COP9 signalosome (CSN), which removes NEDD8 from CUL3, and by the E3 ligase RBX1, which promotes neddylation. The dynamic cycle of neddylation and deneddylation ensures tight temporal control of ubiquitin ligase activity.

### 3.2 Substrate Recognition and Ubiquitination

The Kelch domain of KBTBD13 recognizes specific degron motifs on substrate proteins. Through a combination of yeast two-hybrid screening, co-immunoprecipitation, and ubiquitination assays, the following substrates have been identified:

#### 3.2.1 α-Actinin-1 (ACTN1)

ACTN1 is a key actin-crosslinking protein that organizes actin filaments into parallel bundles and networks. KBTBD13-mediated ubiquitination of ACTN1 targets it for proteasomal degradation. In the context of NEM6, pathogenic KBTBD13 variants lead to altered ACTN1 turnover, resulting in the accumulation of ACTN1 aggregates that contribute to nemaline body formation. The interaction between KBTBD13 and ACTN1 is mediated by the Kelch domain, and disease-causing mutations in the Kelch repeats disrupt this interaction, leading to ACTN1 stabilization.

#### 3.2.2 Actin (ACTA1)

KBTBD13 directly interacts with filamentous actin (F-actin) through its Kelch domain. This interaction is thought to regulate actin dynamics and thin filament length. In muscle fibers from NEM6 patients, there is evidence of altered actin filament organization and reduced thin filament length, which contributes to the reduced force generation observed in these patients.

#### 3.2.3 Tropomyosin Isoforms

KBTBD13 interacts with tropomyosin (TPM3 and TPM2), components of the thin filament that regulate actin-myosin interactions. The interaction between KBTBD13 and tropomyosin may influence the position of tropomyosin on the actin filament, thereby modulating calcium sensitivity and cross-bridge kinetics. This is consistent with the observation that NEM6 patients exhibit slowed muscle relaxation and altered calcium sensitivity.

### 3.3 Signaling Pathways and Regulatory Networks

#### 3.3.1 Ubiquitin-Proteasome System (UPS)

The primary function of KBTBD13 is to direct specific substrates to the 26S proteasome for degradation. The UPS is the major intracellular proteolytic system responsible for removing damaged, misfolded, or short-lived regulatory proteins. By controlling the abundance of sarcomeric proteins, KBTBD13 plays a critical role in maintaining muscle proteostasis.

#### 3.3.2 Autophagy Crosstalk

Emerging evidence suggests crosstalk between the ubiquitin-proteasome system and autophagy. In muscle from NEM6 patients, there is evidence of impaired autophagic flux, with accumulation of autophagosomes and p62/SQSTM1. This may result from the accumulation of ubiquitinated protein aggregates that overwhelm the proteasome, leading to compensatory autophagy activation that becomes insufficient over time.

#### 3.3.3 Calcium Signaling and Muscle Relaxation

NEM6 patients exhibit a distinctive clinical feature of slowed muscle relaxation ("myotonia-like" phenotype without electrical myotonia). Studies using the Kbtbd13R408C knock-in mouse model have revealed that this impaired relaxation results from altered calcium handling and cross-bridge kinetics. Specifically:

- **Reduced SERCA activity**: The sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) shows reduced activity in NEM6 muscle, leading to slower calcium reuptake into the sarcoplasmic reticulum.
- **Altered troponin C sensitivity**: The troponin complex exhibits altered calcium sensitivity, with reduced calcium dissociation rates contributing to prolonged cross-bridge attachment.
- **Increased passive stiffness**: The giant protein titin shows altered stiffness properties in NEM6 muscle, contributing to increased passive tension.

#### 3.3.4 Protein-Protein Interaction Network

STRING and BioGRID analyses reveal that KBTBD13 participates in a complex interaction network:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| CUL3 | Physical (BTB domain) | E3 ligase complex assembly |
| RBX1 | Physical (via CUL3) | E2 recruitment |
| ACTN1 | Physical (Kelch domain) | Ubiquitination and degradation |
| ACTA1 | Physical (Kelch domain) | Actin dynamics regulation |
| TPM3 | Physical (Kelch domain) | Thin filament regulation |
| NEDD8 | Physical (CUL3 modification) | Complex activation |
| COP9 Signalosome | Physical (CUL3 interaction) | Complex inactivation |
| HSP70/HSP90 | Physical (chaperone) | Protein folding and stability |
| p62/SQSTM1 | Physical (aggregate) | Autophagy crosstalk |

### 3.4 Mermaid Diagram: KBTBD13-Mediated Signaling Pathway

```mermaid
sequenceDiagram
    participant NEDD8
    participant CUL3
    participant RBX1
    participant KBTBD13
    participant E2 as "E2 (UbcH5)"
    participant Substrate as "ACTN1/ACTA1/TPM"
    participant Proteasome as "26S Proteasome"
    Note over NEDD8,CUL3: Neddylation activates CUL3
    NEDD8->>CUL3: Covalent attachment
    CUL3->>KBTBD13: BTB domain binding
    KBTBD13->>Substrate: Kelch domain recognition
    RBX1->>E2: Recruitment of E2
    E2->>Substrate: Ubiquitin transfer
    Substrate->>Proteasome: Polyubiquitinated substrate
    Proteasome->>Proteasome: Degradation
    Note over Proteasome: Release of peptides
    CUL3->>CUL3: Deneddylation by CSN
    Note over CUL3: Inactivation and recycling
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Nemaline Myopathy Type 6 (NEM6)

Nemaline myopathy type 6 (NEM6, OMIM #609273) is an autosomal dominant congenital myopathy caused by pathogenic variants in *KBTBD13*. NEM6 is the most prevalent form of nemaline myopathy in the Netherlands, largely due to a founder effect. The condition is characterized by:

- **Muscle weakness**: Predominantly affecting axial, proximal, and distal muscles, with prominent neck flexor weakness.
- **Slowness of movements**: A distinctive clinical feature that distinguishes NEM6 from other nemaline myopathies.
- **Impaired muscle relaxation**: Patients exhibit delayed muscle relaxation after contraction, resembling myotonia but without electrical myotonia on electromyography.
- **Cardiac involvement**: Recent studies have established that KBTBD13 variants can cause dilated cardiomyopathy (DCM), expanding the clinical phenotype.

### 4.2 Founder Mutation: p.Arg408Cys (c.1222C>T)

The most common pathogenic variant in *KBTBD13* is the Dutch founder mutation c.1222C>T, resulting in the substitution of arginine to cysteine at position 408 (p.Arg408Cys, p.R408C). This variant is located in the third Kelch repeat and accounts for the majority of NEM6 cases in the Netherlands.

**Mechanistic consequences of p.R408C**:
- Disruption of the Kelch domain structure, likely affecting substrate binding.
- Altered interaction with actin and tropomyosin, leading to impaired thin filament regulation.
- Reduced ubiquitination of ACTN1, resulting in protein accumulation and nemaline body formation.
- Impaired muscle relaxation due to altered calcium sensitivity and cross-bridge kinetics.

### 4.3 Additional Pathogenic Variants

Several other pathogenic and likely pathogenic variants have been reported:

| **Variant** | **Protein Change** | **Domain** | **Clinical Phenotype** | **Reference** |
|---|---|---|---|---|
| c.1222C>T | p.Arg408Cys | Kelch 3 | NEM6, DCM | |
| c.1222C>G | p.Arg408Gly | Kelch 3 | NEM6 | |
| c.472G>A | p.Glu158Lys | Linker | Core-rod myopathy, late-onset LGMD | |
| c.1219C>T | p.Arg407Trp | Kelch 3 | NEM6 | |
| c.1219C>G | p.Arg407Gly | Kelch 3 | NEM6 | |
| c.1223G>A | p.Arg408His | Kelch 3 | NEM6 | |
| c.1471C>T | p.Arg491Cys | Kelch 4 | NEM6 | |

### 4.4 Genotype-Phenotype Correlations

The p.R408C founder mutation is associated with a relatively homogeneous phenotype characterized by:
- Childhood onset of muscle weakness
- Mild to moderate severity
- Prominent slowness of movements
- Variable cardiac involvement

In contrast, the p.Glu158Lys variant in the linker region is associated with a distinct phenotype resembling late-onset limb-girdle muscular dystrophy (LGMD) with core-rod myopathy pathology. This suggests that the location of the mutation within the protein influences the clinical presentation.

### 4.5 Cardiomyopathy Association

A landmark study by de Winter et al. (2022) established *KBTBD13* as a novel cardiomyopathy gene. The study constructed pedigrees of three families with NEM6 and identified cardiac involvement in a subset of patients. Key findings include:

- **Dilated cardiomyopathy (DCM)**: Some NEM6 patients develop DCM, characterized by left ventricular dilation and reduced systolic function.
- **Arrhythmias**: Conduction abnormalities and arrhythmias have been observed in affected individuals.
- **Subclinical cardiac dysfunction**: Even in the absence of overt cardiomyopathy, subclinical cardiac dysfunction may be present, as detected by advanced imaging techniques.

The Kbtbd13R408C knock-in mouse model recapitulates the cardiac phenotype, showing impaired relaxation kinetics and altered calcium handling in cardiomyocytes. This suggests that the pathomechanism of cardiac involvement shares features with the skeletal muscle pathology.

### 4.6 Core-Rod Myopathy

KBTBD13 mutations have also been associated with core-rod myopathy, a condition characterized by the presence of both cores and nemaline rods in muscle fibers. The p.Glu158Lys variant is a notable example, presenting with late-onset LGMD-like weakness and core-rod pathology. This phenotypic overlap highlights the genetic and clinical heterogeneity of congenital myopathies.

### 4.7 Differential Diagnosis

The differential diagnosis of KBTBD13-related myopathy includes:

- **Other nemaline myopathies**: Caused by mutations in NEB, ACTA1, TPM3, TPM2, TNNT1, CFL2, KLHL40, KLHL41, and LMOD3.
- **Core myopathies**: Central core disease (RYR1), multiminicore disease (SEPN1, RYR1), dusty core disease.
- **Myotonic disorders**: Myotonic dystrophy type 1 and 2, myotonia congenita (CLCN1, SCN4A).
- **Limb-girdle muscular dystrophies**: Various subtypes with overlapping clinical features.
- **Congenital myasthenic syndromes**: May present with fatigable weakness.

### 4.8 Clinical Evaluation and Genetic Testing

The diagnostic workup for suspected KBTBD13-related myopathy includes:

1. **Clinical assessment**: Detailed history and physical examination, with attention to the distinctive features of slowness and impaired relaxation.
2. **Muscle biopsy**: Histological examination may reveal nemaline rods, cores, or both. Electron microscopy can confirm the presence of rods.
3. **Muscle MRI**: May show characteristic patterns of muscle involvement, particularly in the thigh and lower leg muscles.
4. **Genetic testing**: Targeted sequencing of *KBTBD13* or comprehensive myopathy gene panels. Whole-exome or whole-genome sequencing may be required for atypical cases.
5. **Cardiac evaluation**: Echocardiography, ECG, and cardiac MRI are recommended for all patients with confirmed KBTBD13 variants.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of the Ubiquitin-Proteasome System

The ubiquitin-proteasome system is a common target for viral manipulation. Many viruses encode proteins that hijack the host ubiquitination machinery to degrade antiviral factors or to create a favorable environment for viral replication. While direct interactions between KBTBD13 and viral proteins have not been extensively characterized, several lines of evidence suggest potential relevance:

#### 5.1.1 Poxvirus BTB-Kelch Proteins

The BTB/POZ domain was originally identified in poxviruses, where it is found in proteins that modulate host antiviral responses. Poxvirus BTB-Kelch proteins, such as the vaccinia virus EVM150 protein, have been shown to interact with host CUL3 and hijack the CRL3 complex to degrade cellular proteins involved in the innate immune response. The structural similarity between viral BTB-Kelch proteins and KBTBD13 raises the possibility that viral proteins may compete with KBTBD13 for CUL3 binding or that KBTBD13 may be targeted by viral proteins for degradation.

#### 5.1.2 HIV-1 Vpu and BTB Proteins

The HIV-1 accessory protein Vpu interacts with the CRL3 complex through the BTB domain of β-TrCP to degrade CD4 and tetherin. While KBTBD13 is not a known Vpu target, the general principle of viral proteins exploiting CRL3 complexes suggests that KBTBD13 could be involved in host-virus interactions in specific contexts.

### 5.2 Bacterial Effectors and the UPS

Several bacterial pathogens secrete effector proteins that manipulate the host ubiquitin-proteasome system. For example:

- **Shigella flexneri**: The IpaH family of effectors contains leucine-rich repeat (LRR) domains and functions as E3 ligases that ubiquitinate host proteins.
- **Salmonella enterica**: The SopA effector functions as an HECT-like E3 ligase.
- **Legionella pneumophila**: The SidE family of effectors catalyzes non-canonical ubiquitination.

While no direct interactions between KBTBD13 and bacterial effectors have been reported, the muscle-specific expression of KBTBD13 suggests that it may be relevant in the context of bacterial infections affecting skeletal muscle, such as pyomyositis.

### 5.3 Immune Evasion and KBTBD13

The role of KBTBD13 in immune evasion is speculative but plausible. Given that KBTBD13 regulates the degradation of sarcomeric proteins, it may indirectly influence the presentation of muscle-specific antigens to the immune system. In the context of autoimmune myopathies, altered KBTBD13 expression or function could affect the immunogenicity of muscle tissue.

### 5.4 Moyamoya Angiopathy Susceptibility

A recent study by Cabello et al. (2026) identified *KBTBD13* as a potential candidate susceptibility gene for pediatric Moyamoya angiopathy (MMA) through rare variant enrichment analysis. MMA is a rare steno-occlusive cerebrovascular condition that can lead to transient ischemic attacks and strokes. While the primary susceptibility gene is RNF213, the enrichment of rare KBTBD13 variants in MMA patients suggests a possible role in vascular pathology. The mechanistic link between KBTBD13 and vascular biology is unclear but may involve:

- **Endothelial dysfunction**: KBTBD13 may be expressed in endothelial cells, where it could regulate the degradation of proteins involved in vascular remodeling.
- **Smooth muscle cell function**: Vascular smooth muscle cells express KBTBD13, and altered protein turnover could affect vessel wall integrity.
- **Inflammatory signaling**: KBTBD13 may modulate inflammatory pathways that contribute to arterial stenosis.

Further studies are needed to validate these findings and elucidate the underlying mechanisms.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently no FDA-approved therapies specifically targeting KBTBD13. Treatment for NEM6 is primarily supportive and focuses on managing symptoms:

- **Physical therapy**: To maintain muscle strength and flexibility.
- **Respiratory support**: Non-invasive ventilation may be required in severe cases.
- **Cardiac management**: Standard heart failure therapy for patients with DCM, including ACE inhibitors, beta-blockers, and diuretics.
- **Orthopedic interventions**: For scoliosis and joint contractures.

### 6.2 Investigational Therapeutic Approaches

#### 6.2.1 Gene Therapy

Gene therapy approaches for NEM6 are in preclinical development. The most promising strategy involves:

- **KBTBD13 knockdown**: A study by Galli et al. (2026) demonstrated that knockdown of Kbtbd13 restores muscle function in a clinically relevant mouse model of NEM6. This was achieved using antisense oligonucleotides (ASOs) or short hairpin RNA (shRNA) delivered via adeno-associated virus (AAV) vectors. The rationale is that reducing the levels of the mutant protein may alleviate the dominant-negative effects.

- **Allele-specific silencing**: For patients with dominant mutations, allele-specific silencing using RNA interference (RNAi) or CRISPR-Cas9 could selectively target the mutant allele while preserving the wild-type allele.

- **Gene replacement**: For patients with loss-of-function mutations, delivery of a functional KBTBD13 gene via AAV vectors could restore normal protein function. However, this approach is complicated by the dominant inheritance pattern of most NEM6 mutations.

#### 6.2.2 Small-Molecule Modulators

Several small-molecule approaches are being explored:

- **Proteasome inhibitors**: Bortezomib and carfilzomib, which inhibit the proteasome, could potentially reduce the degradation of sarcomeric proteins in NEM6. However, the therapeutic window is narrow, and chronic proteasome inhibition is associated with significant toxicity.

- **CUL3 neddylation inhibitors**: MLN4924 (pevonedistat), a NEDD8-activating enzyme (NAE) inhibitor, blocks the neddylation of CUL3 and thereby inactivates CRL3 complexes. This could reduce the aberrant degradation of substrates in NEM6. However, MLN4924 is a broad-spectrum inhibitor that affects all CRL complexes, limiting its specificity.

- **Calcium modulators**: Given the impaired calcium handling in NEM6, drugs that modulate calcium signaling may be beneficial. For example, dantrolene, which inhibits ryanodine receptor-mediated calcium release, has been considered. However, clinical trials are lacking.

- **Troponin modulators**: Drugs that increase the calcium sensitivity of the troponin complex, such as levosimendan, could potentially improve muscle contraction in NEM6. However, the altered calcium sensitivity in NEM6 may require a different approach.

#### 6.2.3 CRISPR-Cas9 Gene Editing

CRISPR-Cas9-based approaches offer the potential for permanent correction of pathogenic mutations:

- **Homology-directed repair (HDR)**: For point mutations, HDR can be used to correct the mutant allele. However, the efficiency of HDR in post-mitotic muscle cells is low.

- **Base editing**: Adenine base editors (ABEs) and cytosine base editors (CBEs) can convert specific nucleotides without creating double-strand breaks. For the p.R408C mutation (c.1222C>T), an adenine base editor could convert the mutant T back to C, restoring the wild-type sequence.

- **Prime editing**: Prime editors offer greater flexibility and can introduce precise insertions, deletions, and substitutions. This approach is being explored for various genetic diseases and could be adapted for KBTBD13 mutations.

### 6.3 Pharmacogenomic Considerations

The response to supportive therapies may vary based on the specific KBTBD13 mutation:

- **Cardiac medications**: Patients with DCM may respond differently to standard heart failure therapy depending on the severity of cardiac involvement and the presence of arrhythmias.
- **Anesthetic considerations**: Patients with NEM6 may be at increased risk of malignant hyperthermia-like reactions, although this has not been definitively established. Caution is advised with volatile anesthetics and succinylcholine.
- **Drug interactions**: Medications that affect the ubiquitin-proteasome system or calcium handling may have altered efficacy or toxicity in NEM6 patients.

### 6.4 Future Directions

The development of targeted therapies for KBTBD13-related disorders faces several challenges:

1. **Understanding the pathomechanism**: A detailed understanding of how specific mutations affect protein function is essential for developing targeted therapies.
2. **Biomarker development**: Reliable biomarkers are

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)